According a media release earlier today, Bellicum Pharmaceuticals, Inc. has announced dosing of their first patient in a Phase I/II clinical trial of “BP-GMAX-CD1, a novel pharmacologically regulated dendritic cell vaccine for the treatment of prostate cancer.”
Filed under: Drugs in development, Management, Treatment | Tagged: BP-GMAX-CD1, castration-resistant prostate cancer, CRPC, vaccine | 3 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site
